Tirilazad mesylate in acute ischemic stroke: A systematic review

Stroke

Volumn 31, Issue 9, 2000, Pages 2257-2265

  Bath, P M W ^a   Blecic, S ^a   Bogousslavsky, J ^a   Boysen, G ^a   Davis, S ^a   Diez Tejedor, E ^a   Ferro, J M ^a   Gommans, J ^a   Hacke, W ^a   Indredavik, B ^a   Norrving, B ^a   Orgogozo, J M ^a   Ringelstein, E B ^a   Sacchetti, M L ^a   Iddenden, R ^a   Bath, F J ^a   Musch, B C ^a   Brosse, D M ^a   Naberhuis Stehouwer, S A ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cerebral infarction; Meta analysis; Neuroprotective agents; Treatment outcome

Indexed keywords

PLACEBO; TIRILAZAD;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; NEUROPROTECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE;

EID: 0033816426     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.31.9.2257     Document Type: Article

References (63)

1. Effects of the 21-aminosteroid U74006F on experimental head injury in mice
2. Effects of treatment with U-74006F on neurological outcome following experimental spinal cord injury
3. Effect of the 21-aminosteroid U-74006F on cerebral vasospasm following subarachnoid hemorrhage
4. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury
5. Randomised, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: A cooperative study in Europe, Australia, and New Zealand
6. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: A cooperative study in North America
7. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage, part 1: A cooperative study in Europe, Australia, New Zealand, and South Africa
8. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage, part II: A cooperative study in North America
9. 21-Aminosteroid peroxidation inhibitor U74006F protects against cerebral ischemia in gerbils
10. 21-Aminosteroid reduces ion shifts and edema in the rat middle cerebral artery occlusion model of regional ischemia
11. Effect of early treatment with tirilazad (U74006F) combined with delayed thrombolytic therapy in rat embolic stroke
12. The 21-aminosteroid antioxidant tirilazad mesylate, U-74006F, blocks cortical hypoperfusion following spreading depression
13. Effect of U74006F on forebrain ischemia in rats
14. Failure of the lipid peroxidation inhibitor U74006F to improve neurological outcome after transient forebrain ischemia in the rat
15. Evaluation of the pharmacokinetics and tolerability of firilazad mesylate, a 21-aminosteroid free radical scavenger, I: Single-dose administration
16. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger, II: Multiple-dose administration
17. Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day
18. The effect of tirilazad mesylate (U74006F) on cerebral oxygen consumption, and reactivity of cerebral blood flow to carbon dioxide in healthy volunteers
19. Quality of full and final publications reporting acute stroke trials: A systematic review
20. Safety study of tirilazad mesylate in acute stroke (STIPAS)
21. Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS)
22. Randomized trial of tirilazad in acute stroke (RANTTAS)
23. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS)
24. Medical and neurological complications of ischemic stroke: Experience from the RANTTAS trial
25. Safety and efficacy of 6 mg/kg/day tirilazad mesylate with acute ischemic stroke (TESS study)
26. High-dose tirilazad for acute stroke (RANTTAS II)
27. Functional evaluation: The Barthel index
28. Assessment of outcome after severe brain damage: A practical scale
29. Cochrane collaboration handbook
30. Why do all drugs work in animals but none in stroke patients? 1: Drugs promoting cerebral blood flow
31. Why do all drugs work in animals but none in stroke patients? 2: Neuroprotective therapy
32. Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials
33. The effect of tirilazad mesylate on infarct volume of patients with acute ischaemic stroke
34. Body temperature in acute stroke: Relation to stroke severity, infarct size, mortality, and outcome
35. Effects of a novel 21-amino steroid, U74006F, on the rat pituitary-adrenocortical axis
36. Corticosteroids for acute ischaemic stroke
37. Termination of acute stroke studies involving selfotel treatment
38. Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist
39. The Enlimomab Acute Stroke Trial: Final results
40. Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke
41. Calcium antagonists for acute ischemic stroke
42. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke
43. Prostacyclin and analogues in acute ischaemic stroke
44. Pentoxifylline, propentofylline and pentifylline in acute ischaemic stroke
45. Theophylline, aminophylline, caffeine and analogues, in acute ischaemic stroke
46. The International Stroke Trial (IST), a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke
47. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke
48. Thrombolysis for acute ischaemic stroke
49. Tissue plasminogen activator for acute stroke
50. Intravenous thrombolysis with tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Trial (ECASS)
51. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
52. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: The ATLANTIS study: A randomized controlled trial
53. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study: A randomized trial
54. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomised controlled trial
55. The concept of combination therapy in acute ischemic stroke
56. Clinical stroke trials: Guarding against bias
57. Tirilazad for acute ischaemic stroke